Project Grant K99HL183753
Award Date 8/12/26
Completion Date 7/31/28
Dollars Obligated $154K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Palo Alto, CA 94305, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $770,000 on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to fund research unraveling endothelial-cardiomyocyte crosstalk in cardiomyopathy using an integrated multimodal approach. The research examines molecular mechanisms by which endothelial dysfunction contributes to cardiac dysfunction in cardiomyopathy, focusing on cell-to-cell signaling between endothelial cells...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Leland Stanford Junior University a $410,449 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) beginning August 1, 2025, with a completion date of July 31, 2027. This grant supports the development of novel synthetic biology strategies to enhance cell-based therapies for peripheral arterial disease (PAD), a condition affecting over 8 million Americans. The research will...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $509,334 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a high-throughput software package and associated protocols that measure diastolic mechanics in cardiomyocytes using optical microscopy. The project addresses a critical gap in heart failure with preserved ejection fraction (HFpEF) drug discovery. Current tools measure contractile forces and systolic...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $2,339,136 on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of phospholamban in regulating perinuclear calcium signaling and pathological cardiac gene expression as a potential therapeutic target for dilated cardiomyopathy. The funded research examines how phospholamban interacts with the scaffold protein AKAP6B at the myocyte outer nuclear...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $768,830 on July 6, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate immune-fibroblast crosstalk in genetic dilated cardiomyopathy. The research integrates patient-specific induced pluripotent stem cells (iPSCs), three-dimensional cardiac organoids embedded in engineered disease-specific niches, CRISPR-based high-throughput screening, single-cell RNA sequencing,...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $767,249 on June 22, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate computational models for designing organ-scale vasculature in biomanufactured cardiac tissues. The project addresses the need for patient-specific engineered tissues to repair complex congenital heart defects, particularly large ventricular septal defects where current surgical approaches...
- The National Institutes of Health National Heart Lung and Blood Institute awarded The Leland Stanford Junior University $165,888 on April 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) for Project Grant K08HL183852 to investigate T cell contributions to neointima formation in pulmonary hypertension. The research examines how proliferating T cell lineages and their expressed ligands drive neointimal lesion development in pulmonary hypertension, a fatal disease...
- The National Institutes of Health National Heart Lung and Blood Institute awarded The Leland Stanford Junior University $165,488 on March 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to fund research defining the role of transcription factor TCF21 in adventitial fibroblasts during atherosclerosis development. The project will characterize how TCF21 overexpression in adventitial fibroblasts affects atherosclerotic plaque formation using an adventitial...
- The National Heart, Lung, and Blood Institute awarded $1.775 million to Boston Children's Hospital on September 1, 2026, to investigate pericyte-to-smooth-muscle-cell transitions in pulmonary arterial hypertension, under the Cardiovascular Diseases Research program (CFDA 93.837). The research addresses excessive vascular remodeling in pulmonary arterial hypertension by examining how pericytes—specialized mural cells that maintain capillary stability—transition into smooth muscle-like cells under...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $769,846 on July 1, 2026, under Cardiovascular Diseases Research (CFDA 93.837), a Project Grant assistance type. The recipient will develop and apply an integrative genomics toolkit to characterize and engineer edits to regulatory DNA sequences with the goal of reprogramming gene expression for therapeutic applications. The toolkit combines computational models to predict how sequence changes to enhancers...